• Walter Ling, Linda Chang, Maureen Hillhouse, Alfonso Ang, Joan Striebel, Jessica Jenkins, Jasmin Hernandez, Mary Olaer, Larissa Mooney, Susan Reed, Erin Fukaya, Shannon Kogachi, Daniel Alicata, Nataliya Holmes, and Asher Esagoff.
• Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA, USA.
• Addiction. 2014 Sep 1; 109 (9): 1489-500.

Background And AimsNo effective pharmacotherapy for methamphetamine (MA) use disorder has yet been found. This study evaluated sustained-release methylphenidate (MPH-SR) compared with placebo (PLA) for treatment of MA use disorder in people also undergoing behavioral support and motivational incentives.DesignThis was a randomized, double-blind, placebo-controlled design with MPH-SR or PLA provided for 10 weeks (active phase) followed by 4 weeks of single-blind PLA. Twice-weekly clinic visits, weekly group counseling (CBT) and motivational incentives (MI) for MA-negative urine drug screens (UDS) were included.SettingTreatment sites were in Los Angeles, California (LA) and Honolulu, Hawaii (HH), USA.ParticipantsA total of 110 MA-dependent (via DSM-IV) participants (LA = 90; HH = 20).MeasurementsThe primary outcome measure is self-reported days of MA use during the last 30 days of the active phase. Included in the current analyses are drug use (UDS and self-report), retention, craving, compliance (dosing, CBT, MI), adverse events and treatment satisfaction.FindingsNo difference was found between treatment groups in self-reported days of MA use during the last 30 days of the active phase (P = 0.22). In planned secondary outcomes analyses, however, the MPH group had fewer self-reported MA use days from baseline through the active phase compared with the PLA group (P = 0.05). The MPH group also had lower craving scores and fewer marijuana-positive UDS than the PLA group in the last 30 days of the active phase. The two groups had similar retention, other drug use, adverse events and treatment satisfaction.ConclusionsMethylphenidate may lead to a reduction in concurrent methamphetamine use when provided as treatment for patients undergoing behavioral support for moderate to severe methamphetamine use disorder, but this requires confirmation.© 2014 Society for the Study of Addiction.

20 keywords...

hide…